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Edited by Vladimir SkulachevAbstract Bcl-2 protein play important roles in the regulation of
apoptosis. We previously reported that the phosphorylation of
Bcl-2 was augmented by treatment with protein phosphatase 2A
(PP2A) inhibitor; however, the kinase responsible for Bcl-2
phosphorylation had not yet been identiﬁed. In this study, we
identiﬁed extracellular-signal-regulated kinase (ERK) as the
responsible kinase for the phosphorylation of Bcl-2. We also
found that the transmembrane region (TM) deleted form of Bcl-2
(Bcl-2DTM), which was unable to localize on the mitochondria
was constitutively phosphorylated, whereas wild-type Bcl-2 that
localized on the mitochondria, was present in its hypophosphory-
lated form. The phosphorylation of Bcl-2DTM was retarded by
treatment with MAP kinase ERK kinase (MEK) inhibitor and
PP2A did not bind to Bcl-2DTM. These observations suggest that
Bcl-2DTM is constitutively phosphorylated by ERK, but is not
dephosphorylated by PP2A in human tumor cell lines. The
phosphorylation of Bcl-2 resulted in a reduction in anti-apoptotic
function, implying that dephosphorylation promoted the anti-
apoptotic activity of Bcl-2 protein in human tumor cell lines. Thus,
the present ﬁndings suggest that ERK and PP2A are physiolog-
ical regulators of Bcl-2 phosphorylation, and these enzymes exert
an inﬂuence on the anti-apoptotic function of Bcl-2.
 2004 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Apoptosis is a physiological cell suicide mechanism that is
important for the homeostasis and development ofmulticellular
organisms [1]. Thus, the dysregulation of apoptosis contributes
to many diseases, such as cancer, AIDS, and neuronal disease.
The Bcl-2 family proteins are key regulators of apoptosis that
have been classiﬁed into two groups, namely, anti-apoptotic
members (Bcl-2, Bcl-XL and Mcl-1) and pro-apoptotic mem-
bers (Bax, Bad, Bid and Bcl-XS). The bcl-2 gene encodes a* Corresponding author. Fax: +81-48-462-4669.
E-mail address: hisyo@riken.jp (H. Osada).
Abbreviations: CPT, camptothecin; ERK, extracellular-signal-regu-
lated kinase 1 and 2; JNK, c-Jun N-terminal kinase 1 and 2; MAPK,
mitogen-activated protein kinase; MEK, MAP kinase ERK kinase;
PKC, protein kinase C; PLM-F, phoslactomycin F; PP2A, protein
phosphatase 2A; TM, transmembrane region; wt, wild-type
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tosis induced by various stimuli and is overexpressed in many
human tumors [2–5]. Many interpretations of Bcl-2 functions
have been proposed such as inhibition of cytochrome c release
from the mitochondria [6] and regulation of calcium ﬂux [7].
Signal transduction mechanisms in eukaryotic cells make
great use of phosphorylation and dephosphorylation in order
to promote the rapid and reversible modiﬁcation of many
proteins [8]. The activity of the mitogen-activated protein ki-
nase (MAPK) family, which includes extracellular-signal-reg-
ulated kinase (ERK), c-Jun N-terminal kinase (JNK), and p38,
are regulated by phosphorylation [9,10]. ERK are known to
act as anti-apoptotic molecules by transducing survival signals,
whereas the activation of JNK or p38 results in the promotion
of apoptosis [11]. Members of the MAPK family are thought
to be crucial molecules for cell growth, diﬀerentiation, and
apoptosis. Although several substrates of the MAPK family
are already known, the identiﬁcation of additional substrates
will enhance our general understanding of the important roles
played by the MAPK family.
Bcl-2 was found to be phosphorylated after tubulin damage
[12] and during the M phase in the normal cell cycle [13,14].
Several kinases have been proposed to be responsible for
phosphorylating Bcl-2, such as protein kinase C (PKC), JNK,
and cell division cycle 2 (cdc2) kinase [15–17]. Moreover,
studies of Bcl-2 phosphorylation under physiological condi-
tions in human colon, tonsil, and other tissues have been re-
ported [18]. However, the role of Bcl-2 phosphorylation under
physiological conditions remains poorly understood.
Previously, we reported that Bcl-2 was phosphorylated at the
Ser-87 residue in normal human blood cells; however, in tumor
cells, Bcl-2 was dephosphorylated by protein phosphatase 2A
(PP2A) [19]. In this study, we demonstrated that (1) Bcl-2 was
constitutively phosphorylated by ERK at the Ser-87 residue and
is dephosphorylated by PP2A; (2) amutant of Bcl-2 which could
not localize on the mitochondria was constitutively phosphor-
ylated at the Ser-87 residue by ERK; and (3) the localization of
Bcl-2 on themitochondria is required for the dephosphorylation
of ERK-phosphorylated Bcl-2 by PP2A.2. Materials and methods
2.1. Cell lines
Human tumor cell lines HepG2 (Hepatoma), HeLa (Cervical carci-
noma), A431 (Epidermoid carcinoma), and A549 (Lung adenocarci-
noma) were cultured in DMEM supplemented with 10% FCS at 37 Cblished by Elsevier B.V. All rights reserved.
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were cultured in RPMI-1640 supplemented with 10% FCS at 37 C in
an incubator containing 5% CO2.
2.2. Materials
Phoslactomycin F (PLM-F) (PP2A inhibitor) was isolated from
Streptomyces sp. as described previously [20]. Calphostin C (PKC in-
hibitor), KT5720 (c-AMP dependent protein kinase inhibitor), rapa-
mycin (S6 kinase inhibitor), PD98059 (MAPkinase ERKkinase (MEK)
inhibitor), and U0126 (MEK and S6 kinase inhibitor) were purchased
from Calbiochem (San Diego, CA). Camptothecin (CPT, DNA topoi-
somerase I inhibitor) and wortmannin (phosphatidylinositol-3 kinase
(PI-3 kinase) inhibitor) were obtained from Sigma (St. Louis, MO).
SP600125 (JNK inhibitor) was purchased from BIOMOL (Plymouth
Meeting, PA). SB202190 (p38 inhibitor) was a gift from Dr. T. Sudo.
2.3. Plasmids
Human full-length bcl-2 cDNA or mutant-types of bcl-2 cDNAs
were subcloned into a pCI-neo vector (Promega, Madison, WI). Hu-
man full-length ERK2 cDNA was subcloned into the pZeoSV2(+)
vector (Invitrogen, Carlsbad, CA). The nucleotide sequences were
checked by the dideoxynucleotide-chain-termination procedure using
an automated sequencer (Applied Biosystems, Foster City, CA).
2.4. Establishment of stable Bcl-2 overexpressing cell lines
The HepG2 cells were transfected with wild-type Bcl-2 (Bcl-2wt) or
mutant forms of Bcl-2-expression vectors using FuGENE 6 transfec-
tion reagent (Roche Diagnostics AG, Basel, Switzerland), which was
followed by G418 selection. The cells transfected with the pCI-neo
vector were designated as HepG2-Neo cells. The transmembrane re-
gion (TM)-deleted Bcl-2 (Bcl-2DTM) lacks a.a. 219–239 of Bcl-2 [21].
2.5. Western blot analysis
Cells were lysed in lysis buﬀer (10 mM HEPES, 142.5 mM KCl,
5 mM MgCl2, 1 mM EGTA, 0.2% Nonidet P-40, 0.1% aprotinin,
and 1 mM phenylmethylsulfonyl ﬂuoride, pH 7.2) at 4 C. To detect
the mobility shifts in the Bcl-2 protein due to phosphorylation, a
SDS–polyacrylamide gel containing 15% acrylamide and 0.07% N ,N 0-
methylenebisacrylamide was used for separation. Proteins were im-
munoblotted with anti-Bcl-2 antibody (mouse monoclonal, DAKO,
Glostrup, Denmark), anti-a-tubulin antibody (mouse monoclonal,
Sigma), anti-pS87-Bcl-2 antibody (rabbit polyclonal, Oncogene), anti-
ERK2 antibody (mouse monoclonal, BD Biosciences, San Jose, CA),
and anti-PP2A/C antibody (rabbit polyclonal, Calbiochem).
2.6. In vitro kinase assay
Recombinant active ERK2 was purchased from Calbiochem. His6-
tagged recombinant Bcl-2, Bcl-2-S70A, Bcl-2-S87A, and Bcl-2-
S70AS87A that lacked the C-terminal TM domain were expressed in
Escherichia coli. BL21 (DE3) cells and the proteins were puriﬁed using
Ni-nitrilotriacetic acid aﬃnity agarose (Qiagen, Hilden, Germany).
Removal of the TM domain was necessary to produce soluble re-
combinant proteins. The kinase assay was carried out by placing the
recombinant proteins in reaction buﬀer (50 mM Tris–HCl, pH 8.0, 10
mM MgCl2, 1 mM DTT, 10 lCi [c-32P] ATP, and 20 lM unlabeled
ATP) at 30 C for 30 min. The samples were resolved by SDS–PAGE
and visualized by autoradiography.
2.7. Immunoprecipitation
The cells were lysed in TENSV buﬀer (50 mM Tris–HCl, 100 mM
NaCl, 2 mM EDTA, 1 mM Na3VO4, and 1% Nonidet P-40, pH 7.5).
One-milligram aliquots of cell lysate were incubated with anti-Bcl-2
antibodies (Santa Cruz Biotechnology) at 4 C for 2 h. The immune
complexes in the cell lysate were precipitated by centrifugation. The
resultant pellets as well as the whole cell lysates were subjected to SDS–
PAGE, immunoblotting, and detection with either anti-PP2A/C (rab-
bit polyclonal, Calbiochem) or anti-ERK2 (mouse monoclonal, BD
Biosciences) antibodies.
2.8. Fluorescence microscopy
Cells grown on coverslips were treated with 200 nM MitoTracker
Red (Molecular Probes, Eugene, OR) for 30 min and then were ﬁxed
with 3.7% formaldehyde in PBS. After washing the cells with PBS, they
were incubated in 0.1% Triton X-100 in PBS for 5 min, washed once
with PBS, and incubated with anti-Bcl-2 antibody for 30 min. Alexa488 conjugated anti-mouse IgG (Molecular Probes) was used as the
secondary antibody. After washing the samples for an additional three
times, they were incubated with 10 lg/ml Hoechst 33258 (Wako,
Osaka, Japan) for 5 min in the dark in order to stain the nuclei. The
cells were washed 3 more times with PBS and were subsequently ex-
amined using a ﬂuorescence microscope (Olympus, Tokyo, Japan).
2.9. Phosphatase assay
Bcl-2DTM protein was immunoprecipitated with anti-Bcl-2 anti-
bodies (rabbit polyclonal, Santa Cruz Biotechnology, Santa Cruz, CA)
and incubated with alkaline phosphatase (2 U, Sigma) or PP2A (2 U,
Calbiochem) in the presence or absence of phosphatase inhibitors (50
mM NaF, 2 mM sodium orthovanadate, 5 mM EDTA, and 5 mM
EGTA). The resulting samples were electrophoresed and immunob-
lotted with anti-Bcl-2 antibody, as described above.3. Results
3.1. ERK-mediated Bcl-2 phosphorylation at the Ser-87 residue
after PP2A inhibition
To identify the kinase responsible for the phosphorylation of
Bcl-2 after PLM-F treatment, we treated Bcl-2 overexpressed
HepG2 cells (HepG2-Bcl-2wt) with PLM-F in the presence of
8 diﬀerent kinase inhibitors. Treatment with MEK inhibitor,
PD98059, or U0126 reduced the level of PLM-F-induced Bcl-2
phosphorylation, as visualized by a band shift from the slower
to the faster migrating form of the protein detected by Western
blot analysis (Fig. 1A). Treatment with MEK inhibitor,
PD98059, or U0126 completely reduced phosphorylation level
of ERK1/2, but not phosphorylation of p38 and JNK in our
assay system (data not shown). However, treatment with 6
other kinase inhibitors (SB202190, SP600125, rapamycin,
wortmannin, calphostin C, or KT5720) had little eﬀect on
phosphorylation level of Bcl-2 and ERK1/2 (Fig. 1A, and data
not shown). Thus, the results suggested that PLM-F-induced
Bcl-2 phosphorylation is mediated by the MEK-ERK path-
way. We focused on ERK as a potential Bcl-2 kinase after
PLM-F treatment, because ERK are downstream kinases in
the MEK-ERK pathway, and the consensus sequence for the
ERK-phosphorylated site of target proteins is PXn(S/T)P,
where Xn is normally one residue in length, but can in some
cases be two residues that are either neutral or basic in nature
[22]. It has previously been demonstrated that the
(65-PVARTSP-71) and (84-PALSP-88) sequences are both
suitable targets for phosphorylation by ERK. Mutant Bcl-2
proteins (Bcl-2-S70A, Bcl-2-S87A, and Bcl-2-S70AS87A) were
produced in the present study by E. coli. An in vitro kinase
assay demonstrated that ERK phosphorylated Bcl-2, but ERK
did not phosphorylate either Bcl-2-S87A or Bcl-2-S70AS87A
(Fig. 1B). Thus, the ﬁndings indicated that ERK phosphory-
lates Bcl-2 at the Ser-87 residue. To test whether or not Bcl-2
can interact with ERK, co-immunoprecipitation experiments
were performed using the extracts of cells transfected with
human ERK and Bcl-2 or control vector. Immunoprecipita-
tion of Bcl-2wt resulted in co-precipitation with ERK, indi-
cating that these proteins bind to each other in situ (Fig. 1C).
In the control experiments, no ERK protein was detected by
co-precipitation from the extracts of cells that did not express
Bcl-2. These observations suggested that ERK are associated
with Bcl-2 and that they phosphorylate at the Ser-87 residue.
3.2. Characterization of Bcl-2DTM overexpressed HepG2 cells
ERK are known to localize in the cytoplasm and to
translocate into the nucleus upon growth stimulation. In
Fig. 1. ERK phosphorylates Bcl-2 at the Ser-87 residue. (A) The MEK
inhibitors PD98059 and U0126 suppressed the phosphorylation of Bcl-
2 induced by PLM-F treatment. HepG2-Bcl-2wt cells were untreated
(lane 1) or treated with 10 lM PLM-F for 6 h (lanes 2-10) and 8
kinase inhibitors (lanes 3–10); 10 lM SB202190 for 2 h (lane 3),
10 lM PD98059 for 2 h (lane 4), 10 lMU0126 for 2 h (lane 5), 10 lM
SP600125 for 2 h (lane 6), 100 nM rapamycin for 6 h (lane 7), 100 nM
wortmannin for 6 h (lane 8), 100 nM calphostin C for 6 h (lane 9), or
100 nM KT5720 for 6 h (lane 10). The cells were lysed and aliquots of
the cell lysates were analyzed by Western blotting using anti-Bcl-2 and
anti-a-tubulin antibodies. (B) The Ser-87 residue of Bcl-2 is phos-
phorylated by ERK in vitro. An in vitro kinase assay was carried out
using active recombinant ERK and Bcl-2, Bcl-2-S87A, Bcl-2-S70A, or
Bcl-2-S70AS87A proteins. Only Bcl-2 and Bcl-2-S70A were phos-
phorylated to a signiﬁcant level. (C) Association of ERK with Bcl-2 in
situ. HepG2-Neo or HepG2-Bcl-2wt cells were transiently transfected
with pZeo-ERK2 plasmid for 24 h, followed by lysis and immuno-
precipitation (IP) with anti-Bcl-2 antibody. Non-immunoprecipitated
total cell lysates were analyzed in parallel.
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brane through the C-terminal TM [21]. The localization of
these proteins is somehow a contradiction. We examined
whether or not mutant Bcl-2, which could not localize on the
mitochondria, is phosphorylated. To this end, we established
TM-deleted Bcl-2 (Bcl-2DTM) overexpressing HepG2 cells
(designated as HepG2-Bcl-2DTM cells) (Fig. 2A). Immuno-
cytochemistry of Bcl-2 overexpressing cells revealed the dis-
tribution of the protein on the mitochondria. In contrast, the
merge panel of Bcl-2DTM overexpressing cells indicated that
the distribution of Bcl-2DTM is not only in cytosol but also
in nucleus and mitochondria (Fig. 2B). To examine whether
Bcl-2DTM is localized on mitochondria, we puriﬁed mito-
chondria from Bcl-2DTM-expressing cells, and carried out
western blotting analysis for detection of Bcl-2DTM protein.
The data revealed that Bcl-2DTM is not localized at mito-
chondria any more (data not shown). This phenomenon isconsistent with the previous report [21]. Moreover, our data
clearly indicate that Bcl-2DTM was localized in the nucleus.
Indeed, it was reported that phosphorylated form of Bcl-2
was detected in chromosome [23]. Thus, Bcl-2DTM was lo-
calized at cytosol and nucleus, but not mitochondria. Inter-
estingly, Bcl-2wt was detected as a single band in the extracts
of HepG2-Bcl-2wt cells; however, in the extracts of HepG2-
Bcl-2DTM cells, two forms of Bcl-2DTM were clearly
observed (Fig. 2C). Since the slower migrating form of Bcl-
2DTM is thought to be a phosphorylated-form of Bcl-2DTM,
we treated it with alkaline phosphatase in vitro. As shown in
Fig. 2D, treatment with alkaline phosphatase eliminated the
slower migrating form and gave only a faster migrating form,
and this alteration was retarded by phosphatase inhibitor
treatment, suggesting that some of the Bcl-2DTM is consti-
tutively phosphorylated.3.3. Phosphorylation of Bcl-2DTM at the Ser-87 residue by
ERK in situ
Based on the results of a sitespeciﬁc point mutant study and
Western blot analysis using anti-pS87-Bcl-2 antibody, we re-
vealed that Bcl-2DTM is constitutively phosphorylated at the
Ser-87 residue (Fig. 3A and B). In addition, similar results
were observed in other human tumor cell lines, i.e., in HeLa,
A431, A549, and K562 cells (Fig. 3C). We next tested whether
the phosphorylation of Bcl-2DTM is also due to MEK-medi-
ated regulation. As expected, the phosphorylation of Bcl-
2DTM was inhibited by treatment with PD98059 or U0126
(Fig. 3D). Moreover, immunoprecipitation of Bcl-2wt protein
resulted in co-precipitation with ERK, indicating that these
proteins do interact in situ and that Bcl-2DTM does not
quantitatively aﬀect this interaction (data not shown). These
results suggest that Bcl-2DTM is constitutively phosphorylated
by ERK at the Ser-87 residue.
3.4. Association of Bcl-2 protein with PP2A on the
mitochondria
To determine whether the phosphorylation of Bcl-2DTM is
due to dissociation from PP2A, we carried out an immuno-
precipitation assay. As shown in Fig. 4A, the immunoprecip-
itation of Bcl-2wt, but not that of Bcl-2DTM, resulted in the
co-precipitation of PP2A. To conﬁrm whether or not PP2A
directly dephosphorylates Bcl-2 protein in vitro, we treated the
cells with PP2A of the immunoprecipitated and heat-inacti-
vated Bcl-2 protein, which is phosphorylated at the Ser-87
residue. As shown in Fig. 4B, PP2A dephosphorylates immu-
noprecipitated Bcl-2DTM; moreover, the dephosphorylation is
canceled in the presence of PLM-F. Thus, Bcl-2 was dephos-
phorylated by PP2A in vitro, which suggests that the locali-
zation of Bcl-2 on the mitochondria is required for the
dephosphorylation of Bcl-2 by PP2A.
3.5. Abrogation of the anti-apoptotic function of Bcl-2DTM by
phosphorylation at the Ser-87 residue
Finally, we examined the eﬀects of Bcl-2DTM phosphor-
ylation at Ser-87 on anti-apoptotic function. Treatment of
HepG2-Neo cells with 1 lg/ml CPT for 24 h led to apop-
tosis, whereas such drug-induced apoptosis was clearly re-
duced in HepG2-Bcl-2wt cells. In approximately 40% of the
HepG2-Bcl-2DTM cells, apoptosis was induced following
CPT treatment; however, in HepG2-Bcl-2-S87ADTM cells,
Fig. 2. Characterization of Bcl-2DTM overexpressed HepG2 cells. (A) Schematic diagram of the Bcl-2wt and Bcl-2DTM proteins. The TM (residues
219–237) is denoted by a black box and the Bcl-2 homology (BH) domains (residues 10–30 for BH4, residues 93–107 for BH3, residues 136–155 for
BH1, and residues 187–202 for BH2) are designated by hatched boxes. (B) Subcellular localization of Bcl-2 and Bcl-2DTM proteins. Exponentially
growing HepG2 cells transfected with pCI-neo, pCI-bcl-2, or pCI-bcl-2DTM were stained with Hoechst 33258 (for nuclei; blue), MitoTracker Red
(for mitochondria; red), and anti-Bcl-2 antibody (green), and the cells were observed using ﬂuorescence microscopy. (C) Expression of Bcl-2 and Bcl-
2DTM proteins. Exponentially growing HepG2, HepG2-Neo, HepG2-Bcl-2wt, and HepG2-Bcl-2DTM cells were lysed and the total cell lysates were
analyzed by Western blotting using anti-Bcl-2 and anti-a-tubulin antibodies. (D) Phosphorylation of Bcl-2DTM in situ. An exponentially growing
cell line expressing Bcl-2DTM was lysed and incubated with alkaline phosphatase in the presence or absence of phosphatase inhibitors. The resulting
samples were analyzed by Western blotting using anti-Bcl-2 antibody.
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cells underwent apoptosis (Fig. 5). Thus, we concluded that
the constitutive phosphorylation of Bcl-2DTM at the Ser-87
residue reduces the potency of its anti-apoptotic function.4. Discussion
Bcl-2 was originally identiﬁed as the proto-oncogene in-
volved in the t(14; 18) translocation in human follicularlymphoma [24]. Bcl-2 turned out to be an unusual oncogene
in that rather than providing a proliferative advantage to the
cell, it enhanced its capacity to survive under sub-optimal
conditions. Previous observations have thus suggested that
changes in the regulation of Bcl-2 might inﬂuence the course
of tumorigenesis and/or in the acquisition of drug resistance
by tumor cells. Indeed, the overexpression of Bcl-2 has been
observed in several types of human tumors [25–27]. For ex-
ample, it has been reported that a phosphorylated form of
Bcl-2 occurs in human tissues such as the colon [18]; however,
Fig. 3. Phosphorylation of Bcl-2DTM at the Ser-87 residue by ERK in situ. (A) and (B) Phosphorylation of Bcl-2DTM at the Ser-87 residue in situ.
Exponentially growing cell lines expressing Bcl-2wt or mutant forms (Bcl-2DTM, Bcl-2-S70ADTM, Bcl-2-S87ADTM, or Bcl-2-S70AS87ADTM) of
Bcl-2 or carrying the control construct (Neo) were lysed and aliquots were analyzed by Western blotting using anti-Bcl-2 and anti-a-tubulin anti-
bodies (A) and anti-pS87-Bcl-2 antibody (B). (C) Phosphorylation of Bcl-2DTM protein in several human tumor cell lines. Exponentially growing
HeLa, A431, A549, and K562 cells were transiently transfected with pCI-neo, pCI-bcl-2, or pCI-bcl-2DTM. Total cell lysates were analyzed by
Western blotting using anti-Bcl-2 antibody. (D) The MEK inhibitors PD98059 and U0126 suppressed the phosphorylation of Bcl-2DTM. HepG2-
Bcl-2DTM (upper) or HepG2-Bcl-2wt (lower) cells were untreated (lane 1) or treated with 10 lM SB202190 for 2 h (lane 2), 10 lM PD98059 for 2 h
(lane 3), 10 lMU0126 for 2 h (lane 4), 10 lM SP600125 for 2 h (lane 5), 100 nM rapamycin for 18 h (lane 6), 100 nM wortmannin for 18 h (lane 7),
100 nM calphostin C for 18 h (lane 8), or 100 nM KT5720 for 18 h (lane 9). The cells were lysed and aliquots of the cell lysates were analyzed by
Western blotting using anti-Bcl-2 and anti-a-tubulin antibodies.
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poorly understood.
Many interpretations of the purpose of Bcl-2 phosphoryla-
tion have been proposed; for example, it has been suggested
that Bcl-2 phosphorylation is involved in the inactivation of
anti-apoptotic function [12,16,28–30], marker of M phase
events [31,32], and promotes anti-apoptotic mechanisms [33–
36]. Here, we revealed that the expression of Bcl-2DTM, con-
stitutively phosphorylated by ERK, demonstrated roughly
comparable decreases in anti-apoptotic activity compared with
Bcl-2-S87ADTM (Fig. 5). These observations indicate that the
phosphorylation of Bcl-2 results in the inactivation of anti-
apoptotic function; thus, the present ﬁndings are consistent
with those of previous reports [12,16,28–30]. However, our
ﬁndings remain in contrast with the observations obtained by
using a diﬀerent system, in which unphosphorylated Bcl-2
displays less protection in certain cell lines [33–36]. Thus, it islikely that the regulation of the anti-apoptotic function of
Bcl-2 by phosphorylation is dependent on cell-type speciﬁc
factors that are as yet undeﬁned.
We previously reported that the Ser-87 residue of Bcl-2 is
constitutively phosphorylated in human normal blood cells
and is dephosphorylated by PP2A [19]. Moreover, Ruvolo
et al. [33,34] reported that Bcl-2 is dephosphorylated by
mitochondrial PP2A in ceramide-mediated regulation. The
ﬁndings of the present study suggest that ERK and PP2A
co-regulate the status of Bcl-2 phosphorylation, without any
external stimuli in human tumor cell lines. We identiﬁed the
ERK as being Bcl-2DTM kinase (Figs. 1B and 3D). It has
been proposed that ERK function as negative regulators of
apoptosis by transducing survival signals [11]. In this study,
we showed that ERK has the capacity to phosphorylate and
inactivate the anti-apoptotic activity of Bcl-2, and thus they
may act both as negative and as positive regulators of the
Fig. 4. Dephosphorylation of Bcl-2 by PP2A on the mitochondria. (A)
Association of PP2A with Bcl-2wt, but not with Bcl-2DTM. HepG2-
Neo, HepG2-Bcl-2wt, or HepG2-Bcl-2DTM cells were lysed and
aliquots of the cell lysates were immunoprecipitated (IP) with anti-Bcl-
2 antibody. In addition, non-IP cell lysates were analyzed by Western
blotting. (B) Dephosphorylation of Bcl-2DTM by PP2A in vitro. Bcl-
2DTM protein was immunoprecipitated with anti-Bcl-2 antibody,
boiled for 3 min to quench the endogenous enzymes, and incubated
with PP2A in the absence or presence of 100 lM PLM-F. The samples
were analyzed by Western blotting using anti-Bcl-2 antibodies.
Fig. 5. Partial inhibition of CPT-induced apoptosis by Bcl-2DTM. The
eﬀects of Bcl-2, Bcl-2DTM, or Bcl-2-S87ADTM overexpression on
CPT-induced apoptosis. Each cell line was untreated (open bars) or
treated (solid bars) with 1 lg/ml CPT for 24 h. Dead cells were assessed
by trypan blue dye exclusion assay. Values are meansS.D. of qua-
druplicate determinations.
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precipitate with Bcl-2 protein; these results are in agreement
with those of Deng et al., who showed that ERK co-localize
with Bcl-2 [37]. Moreover, the eﬀect of MEK inhibitors
completely depends on the conditions, MEK5 is usually
more sensitive than MEK1/2 [38]. Thus, we could not ex-
clude the possibility that PP2A inhibitor-induced Bcl-2
phosphorylation might be mediated by MEK1-ERK1/2 and/
or MEK5-ERK5 pathways.
It has been reported that Bcl-2 is phosphorylated by un-
identiﬁed kinase(s) after treatment with tubulin binder
[12,28,29]. In this study, we demonstrated that the phos-phorylation of Bcl-2wt by PLM-F treatment and the con-
stitutive phosphorylation of Bcl-2DTM are mediated by
ERK. Thus, we concluded that the ERK in this context are
Bcl-2 kinases under physiological conditions in the absence
of speciﬁc stimuli. On the other hand, the treatment of cells
with PD98059 or U0126 failed to inhibit tubulin binder-in-
duced Bcl-2 phosphorylation (data not shown). Therefore, it
appears that the MEK-dependent pathway is not required
for tubulin binder-induced Bcl-2 phosphorylation. Further
study will be necessary in order to identify diﬀerent Bcl-2
kinases and to clarify the role of Bcl-2 phosphorylation
under diﬀerent conditions, such as tubulin binder stimulation
and the M phase of the normal cell cycle.
The present results, when taken together with those of our
previous study, lead to the following three conclusions, which
suggest a correlation between Bcl-2 phosphorylation status
and tumorigenesis. (1) In normal human blood cells, Bcl-2 is
phosphorylated at the Ser-87 residue; furthermore, the anti-
apoptotic function of Bcl-2 might be inactivated by this
mechanism [19]. (2) In human tumor cell lines, the Ser-87
residue of Bcl-2 is phosphorylated by ERK and this residue is
immediately dephosphorylated by PP2A on the mitochondria.
Thus, in human tumor cell lines, Bcl-2 is constitutively
dephosphorylated and its anti-apoptotic function is activated.
(3) Bcl-2DTM interacts with ERK, but it cannot interact with
PP2A. Thus, Bcl-2DTM is constitutively phosphorylated by
ERK and its anti-apoptotic function is weakened. Phosphor-
ylation of Bcl-2DTM at the Ser-87 residue results in a decrease
in anti-apoptotic function, whereas dephosphorylation acti-
vates the anti-apoptotic function in human tumor cell lines.
These observations suggest that phosphorylation regulated by
ERK and PP2A may have a signiﬁcant impact on the onco-
genic activity of Bcl-2.
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